相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。T.E.A. Study: three-day ertapenem versus three-day Ampicillin-Sulbactam
Fausto Catena et al.
BMC GASTROENTEROLOGY (2013)
Prospective randomized comparison study of piperacillin/tazobactam and meropenem for healthcare-associated pneumonia in Japan
Yoshihiro Yamamoto et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2013)
β-Lactam/β-Lactam Inhibitor Combinations for the Treatment of Bacteremia Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli: A Post Hoc Analysis of Prospective Cohorts
Jesus Rodriguez-Bano et al.
CLINICAL INFECTIOUS DISEASES (2012)
Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study
Jose A. Vazquez et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Prevalence and characterisation of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates in healthy volunteers in Tunisia
R. Ben Sallem et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2012)
Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum -lactamases: a systematic review and meta-analysis
Konstantinos Z. Vardakas et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
High community faecal carriage rates of CTX-M ESBL-producing Escherichia coli in a specific population group in Birmingham, UK
Nimal H. Wickramasinghe et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Fecal Carriage of ESBL-Producing E. coli and K. pneumoniae in Children in Guinea-Bissau: A Hospital-Based Cross-Sectional Study
Joakim Isendahl et al.
PLOS ONE (2012)
Prevalence of faecal ESBL carriage in the community and in a hospital setting in a county of Southern Sweden
H. Stromdahl et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2011)
Comparison of Sulbactam-Cefoperazone with Carbapenems as Empirical Monotherapy for Febrile Neutropenic Children with Lymphoma and Solid Tumors
Haci Ahmet Demir et al.
PEDIATRIC HEMATOLOGY AND ONCOLOGY (2011)
Piperacillin/tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital
N. Saltoglu et al.
CLINICAL MICROBIOLOGY AND INFECTION (2010)
Piperacillin-tazobactam Versus Carbapenem Therapy With and Without Amikacin as Empirical Treatment of Febrile Neutropenia in Cancer Patients: Results of an Open Randomized Trial at a University Hospital
Nefise Oztoprak et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2010)
Imipenem-cilastatin versus piperacillin-tazobactam as monotherapy in febrile neutropenia
Sema Vural et al.
PEDIATRICS INTERNATIONAL (2010)
Tazobactam/piperacillin for moderate-to-severe pneumonia in patients with risk for aspiration: Comparison with imipenem/cilastatin
Isao Ito et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2010)
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia:: a randomized, open-label, multicenter study
Alvaro Rea-Neto et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients
Albert E. Yellin et al.
AMERICAN JOURNAL OF SURGERY (2007)
Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia - a double blind prospective multicentre study
D. V. Schmitt et al.
INFECTION (2006)
Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention
AS Dela Pena et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2006)
Comparison of piperacillin/tazobactam and imipenem/cilastatin, both in combination with tobramycin, administered every 6 h for treatment of nosocomial pneumonia
Maniari Joshi et al.
RESPIRATORY MEDICINE (2006)
Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial
BA Lipsky et al.
LANCET (2005)
Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation:: a randomised, multicentre trial
G Reich et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Antibiotic therapy for Klebsiella pneumoniae bacteremia:: Implications of production of extended-spectrum β-lactamases
DL Paterson et al.
CLINICAL INFECTIOUS DISEASES (2004)
Measuring inconsistency in meta-analyses
JPT Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: Results of a prospective, randomized, double-blind multicenter study
DR Graham et al.
CLINICAL INFECTIOUS DISEASES (2002)
Piperacillin 2 g/tazobactam 0.5 g is as effective as imipenem 0.5 g/cilastatin 0.5 g for the treatment of acute uncomplicated pyelonephritis and complicated urinary tract infections
KG Naber et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2002)
Initial empiric therapy of febrile neutropenia with antibiotic monotherapy.: Piperacillin/tazobactam versus imipenem/cilastatin (1994-1996)
R Figuera et al.
MEDICINA CLINICA (2001)
Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs)
DL Paterson
CLINICAL MICROBIOLOGY AND INFECTION (2000)
分享论文
